Neuroprotection for Ischemic Stroke: Two Decades of Success and Failure

被引：250

作者：

Cheng Y.D. ^{[1
]}

Al-Khoury L. ^{[1
]}

Zivin J.A. ^{[1
]}

机构：

[1] Stroke Center, University of California School of Medicine, University of California San Diego, La Jolla

来源：

NeuroRX | 2004年 / 1卷 / 1期

关键词：

anti-inflammatory agents; free radical scavengers; glutamate antagonists; ion channel blocks; neural stem cells; Neuroprotection trials; neurotrophic factors;

D O I：

10.1602/neurorx.1.1.36

中图分类号：

学科分类号：

摘要：

Alteplase (rt-PA) is the first therapy successfully developed for acute stroke therapy. The success of rt-PA spurred development of new avenues for acute stroke management. For the last two decades, a great deal of attention has been paid to neuroprotective therapies. Initial preclinical studies demonstrated numerous drugs are effective for treating acute stroke in animal models; however, subsequent clinical trials have been frustrating, and none of the agents has proven effective. The various outcomes of preclinical and clinical trials have been the subject of much discussion. In this article, we review some key neuroprotective trials and the possible reasons for their failures. By identifying the discrepancies between preclinical studies and clinical trials, we may be able to set guidelines for future effective trials. © 2004 The American Society for Experimental NeuroTherapeutics, Inc.

引用

页码：36 / 45

页数：9

共 92 条

[1] American Stroke Association, Heart Disease and Stroke Statistics-2003 Updat, (2003)
[2] Marshall J., Duffin K., Green A., Ridley R., NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species, Stroke, 32, pp. 190-198, (2001)
[3] Shimizu-Sasamata M., Kano T., Rogowska J., Wolf G., Moskowitz M., Lo E., YM872, a highly water-soluble AMPA receptor antagonist, preserves the hemodynamic penumbra and reduces brain injury after permanent focal ischemia in rats, Stroke, 29, pp. 2141-2148, (1998)
[4] Lapchak P., Et al., A novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits, Stroke, 33, pp. 2279-2284, (2002)
[5] Steen P., Newberg L., Milde J., Michenfelder J., Nimodipine improves cerebral blood flow and neurologic recovery after complete cerebral ischemia in the dog, J Cereb Blood Flow Metab, 3, pp. 38-43, (1983)
[6] Kidwell C., Liebeskind D., Starkman S., Saver J., Trends in acute ischemic stroke trial through the 20th century, Stroke, 32, pp. 1349-1359, (2001)
[7] Zivin J., Grotta J., Animal stroke models: they are relevant to human disease, Stroke, 21, pp. 981-983, (1990)
[8] Gorelick P., Neuroprotection in acute ischaemic stroke: a tale of for whom the bell tolls, Lancet, 355, pp. 1925-1926, (2000)
[9] Morgenstern L., What have we learned from clinical neuroprotective trials?, Neurology, 57, (2001)
[10] Gladstone D., Black S., Hakim A., Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions, Stroke, 33, pp. 2123-2136, (2002)

← 1 2 3 4 5 6 7 8 9 10 →